AKT1 and cancer: Up to half of tumor cell lines, however, display resistance to TRAIL [11] and this resistance appears to be mediated through the regulation of cFLIP, Bcl-2 family members, IAP proteins, and activation of PI3K/Akt and extracellular signal-regulated kinases (ERK) survival pathway [12-14], which suggesting that treatment with TRAIL alone may be insufficient for cancer therapy.